Pathological response to neoadjuvant therapy correlates to RFS, OS in stage III melanoma

Source: Healio, February 2021

Pathological response should be an early surrogate endpoint for clinical trials of neoadjuvant therapy for melanoma, according to results of a pooled analysis published in Nature Medicine.

Pathological complete response (pCR) also should be a new benchmark for drug development and approval, study authors concluded.

“Neoadjuvant systemic therapy has the potential to reduce tumor burden to facilitate and likely reduce the extent of surgical resection for stage III melanoma, as well as provide prognostic information to allow personalized follow-up and alternative adjuvant therapy in poor-prognosis patients,” Alexander Menzies, BSc(Med), MBBS(Hons), FRACP, PhD, medical oncologist and associate professor of melanoma medical oncology at Melanoma Institute Australia, told Healio.